News

Reverdia starts its bio-succinic acid plant
Enlarge image

BusinessItalyNetherlandsFrance

Reverdia starts its bio-succinic acid plant

17.12.2012 - Reverdia has started industrial production of bio-succinic acid at a new production plant with an annual capacity of 10,000 metric tons.

The joint venture between Dutch DSM NV and French starch producer Roquette Frères has begun operations in Cassano Spinola, Italy, at a commercial-scale plant producing Biosuccinium™ sustainable succinic acid. The company said the plant, which has a capacity of about 10,000 tonnes/yr, was unique in its kind, being the world’s first dedicated large-scale plant for the production of succinic acid from renewable resources. However, according to US-based BioAmber Inc, which fused BioAmber SAS and US company DNP Green Technology in 2010, it has been producing the chemical building block at 4,000 tonnes/yr since 2009.

Both producers rely on genetically engineered E.coli strains for producing the compound, that is being used to make bioplastics, chemical internmediates such as 1,4 butanediol, solvents, coatings, and phthalate-free plasticisers. As the market for bio-based succinic acid is expected to grow rapidly in the next few years, other joint-ventures such as Succinity or US-based Myriant Inc. are building production facilities. Reverdia will market its bio-succinium in collaboration with Helm.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/reverdia-starts-its-bio-succinic-acid-plant.html

R&DEUBelgium

18.12.2014 IMI has launched a €115m call for proposals involving a project in collaboration with the Bill and Melinda Gates Foundation to improve vaccines against whopping cough in children.

PoliticsEUPolandItalySpainUK

16.12.2014 Two consortia combined of 144 European companies, research institutes and universities have been selected for funding by the EIT in the areas of health and raw materials. Both clusters are set to acquire €1.1bn over the next seven years.

M&ALuxembourg

11.12.2014 Luxembourg bio-analytical testing company Eurofins Scientific has signed an agreement to acquire Boston Heart Diagnostics Corp. for an initial €112m.

StudySwitzerlandEU

10.12.2014 When it comes to the biggest investors in Research and Development (R&D) Swiss pharma top dogs Novartis and Roche have defended their positioning among the top ten companies worldwide – according to a recently published EU study.

FinancingUKSpain

09.12.2014 British drug delivery specialist Midatech Pharma plc floated on the London stock market. It is the third biotech IPO on the AIM market this year.

CooperationAustria

05.12.2014 Austrian contract research company VTU has entered into a development and commercialisation agreement with US company RCT. The partners want to combine both companies' Pichia pastoris protein production technologies under VTU's roof.

FinancingDenmark

03.12.2014 Danish biotech pharma Ascendis has successfully completed a €48m Series D financing round. The funding is expected to support its late-stage clinical trials to push its lead drug into Phase III trials.

RegulationUKFranceGermanySpain

01.12.2014 In spite of innovative new medicines on the market, the UK and Germany lag behind other countries and continue to use older medicines - especially in the treatment of cancer. French and Spanish patients, on the other hand, benefit much earlier from medical innovation.

Events

All Events

Current issue

All issues

Product of the week

Products